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Immunizing most of the global population with effica-
cious vaccines is the safest, fastest, and most reliable solu-
tion to emerge from the current COVID-19 pandemic. Ex-
tensive research efforts have produced a few vaccines with 
proven efficacy and acceptable safety profiles to achieve this 
purpose. Nonetheless, the limited manufacturing capacity 
and the logistics of vaccine approvals, production, ship-
ment, and distribution to the target population, lead to sig-
nificant delays that require both prioritizations of the vul-
nerable population groups and equitable distribution of the 
vaccines around the world.1 
Simulations have shown that an equitable global vaccine 
roll-out strategy will avert twice the worldwide deaths of 
rolling vaccines out to high-income countries (HICs) first.2 
Despite these recommendations from global health experts 
and the World Health Organization (WHO), it is currently 
estimated that more than 10% of the global population have 
been vaccinated. However, most of them are in HICs; the 
share of the population that has received at least one dose 
of the COVID-19 vaccine is 14% and 1% in lower-middle-
income countries and low-income countries, respectively 
(Figure 1). 
This inequitable access to vaccines has consequences 
and limitations on academic and clinical work in low- and 
middle-income countries (LMICs). Not only do some coun-
tries require proof of vaccinations to apply for travel visas, 
but these countries set a list of specific vaccines that are 
recognized by them which render individuals with other 
WHO-approved vaccinations ineligible.3,4 For example, 
people who are fully vaccinated with some vaccines includ-
ing BBIBP-CorV "Sinopharm, China" and CoronaVac “Sino-
vac, China” are not recognized in Europe as such. Therefore, 
millions of vaccinated people in LMICs are barred from 
traveling to Europe. For example, a colleague in our team 
has won a competitive travel scholarship to the European 
Association of Neurosurgical Societies meeting 2021 in 
Hamburg, Germany where he is scheduled to make two pre-
sentations. However, he will not be able to travel because 
he did not have access to the vaccines accepted in Germany 
(Table 1). 
In Egypt, the government successfully signed deals to se-
cure 120 million doses of different vaccines as Sinopharm 
and AstraZeneca’s.7 However, owing to the non-equitable 
Figure 1. A Pie chart of the share of the population 
that has received at least one dose of COVID-19 
vaccines, disaggregated by country-income level, 
Data as of July 7, 2021, to account for lag in-country 
reporting, Source: Our World in Data, World Bank, 
United Nations 
global vaccine rollout strategy, Egypt has received only 10 
million doses of its full share of COVID-19 vaccines. 
Although the Sinovac and Sinopharm vaccines have been 
endorsed by the WHO Strategic Advisory Group of Experts 
and are now listed as WHO-approved COVID-19 vaccines 
for emergency use, European countries, United Kingdom, 
Canada, and other HICs still do not recognize these vaccines 
(Table 1). 
LMICs citizens face more obstacles to resume their acad-
emic and research duties compared to their counterparts in 
HICs. The authors propose that all COVID-19 vaccines that 
meet the standards of the WHO in terms of safety and effi-
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Table 1. A list of WHO approved vaccines and their 
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Submitted: August 16, 2021 CEST, Accepted: September 12, 
2021 CEST 
This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International License 
(CCBY-4.0). View this license’s legal deed at http://creativecommons.org/licenses/by/4.0 and legal code at http://creativecom-
mons.org/licenses/by/4.0/legalcode for more information. 
How the limited recognition of WHO-approved COVID-19 vaccines harm researchers of the low-and middle-income countries - A...
Journal of Global Health Economics and Policy 2
REFERENCES 
1. Annex A: COVID-19 vaccine and health 






entation. Accessed September 12, 2021. 
2. Estimating the effect of cooperative versus 
uncooperative strategies of COVID-19 vaccine 




y. Accessed September 12, 2021. 
3. German Embassy in Cairo. Homepage, Travel & 
Visa Instructions [internet]. German Embassy in 
Cairo Website. https://kairo.diplo.de/eg-ar. Accessed 
August 15, 2021. 
4. Paul Ehrlich Institute; Vaccination certificate 
within the meaning of the COVID-19 Protective 
Measures Exception Ordinance and the Coronavirus 
Entry Ordinance [Internet. Federal Ministry of Health 
in Germany. https://www.pei.de/DE/newsroom/dossie
r/coronavirus/coronavirus-inhalt.html?nn=169730&c
ms_pos=3. Accessed July 30, 2021. 




s. Published September 8, 2021. Accessed September 
12, 2021. 
6. Canada H. Government of Canada. COVID-19 
Vaccines: Authorized vaccines - Canada.ca. https://w
ww.canada.ca/en/health-canada/services/drugs-healt
h-products/covid19-industry/drugs-vaccines-treatme
nts/vaccines.html. Published June 2, 2021. Accessed 
September 12, 2021. 
7. Arabic RT. Egypt’s Health Secretary says Egypt has 
signed deals to secure 120 million doses of COVID-19 
vaccines. https://ar.rt.com/qqwq. Accessed July 30, 
2021. 
How the limited recognition of WHO-approved COVID-19 vaccines harm researchers of the low-and middle-income countries - A...
Journal of Global Health Economics and Policy 3
